Global Assisted Reproductive Technology ART Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Assisted Reproductive Technology ART Market Size

• The global assisted reproductive technology ART market size was valued at USD 30.88 billion in 2024 and is expected to reach USD 58.87 billion by 2032, at a CAGR of 8.40% during the forecast period
• The market growth is largely fuelled by the growing adoption and technological progress within fertility treatment procedures and reproductive healthcare services, leading to increased digitalization and efficiency in clinical outcomes
• Furthermore, rising consumer demand for effective, personalized, and minimally invasive fertility solutions is establishing Assisted Reproductive Technology (ART) as the preferred approach for individuals and couples facing infertility challenges. These converging factors are accelerating the uptake of ART solutions, thereby significantly boosting the industry's growth

Assisted Reproductive Technology ART Market Analysis

• Assisted Reproductive Technology (ART) encompasses medical procedures used to address infertility, involving the handling of eggs, sperm, or embryos. These technologies are increasingly vital components of modern healthcare, offering hope and solutions to individuals and couples facing fertility challenges. The widespread adoption of ART is driven by increasing infertility rates, advancements in medical technology, and growing awareness of fertility treatment options
• The escalating demand for ART is primarily fuelled by rising infertility rates caused by factors such as lifestyle changes, delayed parenthood, and various medical conditions. Furthermore, continuous advancements in ART techniques, including improved success rates for procedures such as In Vitro Fertilization (IVF) and the development of new genetic screening methods, are making these treatments more accessible and effective
•  North America dominated the assisted reproductive technology (ART) market with the largest revenue share of 34.9% in 2024, characterized by advanced healthcare infrastructure, high disposable incomes, and favorable reimbursement policies. The region, particularly the U.S., witnessed substantial growth in ART procedures, driven by increasing infertility rates, greater awareness of fertility treatments, and technological advancements introduced by leading fertility clinics and biotech companies
• Asia-Pacific is expected to be the fastest-growing region in the assisted reproductive technology (ART) market during the forecast period with a CAGR of 7.4%. This growth is attributed to increasing infertility rates, rising awareness of fertility treatments, improving healthcare infrastructure, and rising disposable incomes in countries such as China, Japan, and India
• In Vitro Fertilization (IVF) dominated the assisted reproductive technology (ART) market with a market share of 56.7% in 2024. This dominance is driven by IVF's higher success rates, widespread usage, and continuous technological advancements, making it the most effective method for treating various causes of infertility

Report Scope and Assisted Reproductive Technology ART Market Segmentation     

Assisted Reproductive Technology ART Market Trends

“Improved Efficiency and Personalization in Fertility Treatments”

• A significant and accelerating trend in the global assisted reproductive technology (ART) market is the growing emphasis on enhancing treatment efficiency and personalization through technological and clinical advancements. These developments are improving diagnostic precision, streamlining procedures, and boosting success rates in fertility care
  • For instance, modern embryo assessment tools and advanced imaging techniques are enabling embryologists to better evaluate embryo viability, thereby increasing the chances of successful implantation and pregnancy outcomes
• Advancements in treatment planning are allowing clinicians to customize hormone stimulation protocols and optimize the timing of procedures based on individual patient profiles. This patient-centric approach is improving overall efficacy and minimizing complications
• The integration of ART solutions with electronic health records (EHRs), remote monitoring tools, and fertility management software is facilitating better communication between patients and providers, ensuring real-time tracking, informed decision-making, and improved treatment adherence
• This trend toward more streamlined, responsive, and personalized fertility solutions is fundamentally reshaping patient experiences and expectations. As a result, leading companies are focusing on innovations that improve workflow efficiency and deliver higher-quality outcomes in assisted reproduction
• The demand for technologically advanced, patient-friendly ART procedures is growing rapidly across fertility clinics and hospitals, driven by rising infertility rates, greater awareness, and evolving lifestyle factors worldwide

Assisted Reproductive Technology ART Market Dynamics

Driver

“Growing Need Due to Rising Infertility Rates and Delayed Parenthood”

• The increasing prevalence of infertility globally, coupled with a growing trend of delayed parenthood due to lifestyle choices, career priorities, and medical conditions, is a significant driver fueling demand for Assisted Reproductive Technology (ART)
  • For instance, in April 2024, FUJIFILM Irvine Scientific announced the expansion of its fertility media production facility in Europe, reflecting rising demand and increased investment in ART infrastructure. Such developments by key players are expected to accelerate ART industry growth during the forecast period
• As couples become more aware of fertility treatment options and seek medically guided solutions, ART procedures offer advanced methods such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and cryopreservation, providing higher chances of conception
• Furthermore, the growing societal acceptance of ART and its inclusion in public and private insurance programs in many countries are making fertility treatments more accessible and affordable
• The convenience of personalized treatment plans, improved clinical success rates, and access to technologically advanced fertility centers are key factors propelling the adoption of ART solutions in both developed and developing markets. In addition , increased awareness through digital platforms and fertility education campaigns further contributes to market growth

Restraint/Challenge

“Concerns Regarding Ethical Issues and High Treatment Costs”

• Concerns surrounding the ethical implications of embryo manipulation, third-party reproduction, and genetic screening continue to pose challenges to broader ART adoption. These issues often raise legal, cultural, and religious debates, particularly in conservative societies, impacting patient decisions and regulatory support
  • For instance, ongoing debates around embryo selection and surrogacy laws in various countries have led to inconsistencies in ART regulation, which can deter potential users and hinder clinic operations
• Addressing these concerns through transparent ethical guidelines, patient counseling, and consistent regulatory frameworks is essential for building trust and acceptance. Key institutions and associations are advocating for clearer standards to support both patients and clinicians
• In addition, the relatively high cost of ART procedures, including medications, laboratory fees, and multiple treatment cycles, can be a barrier to adoption for middle- and low-income individuals, especially in regions with limited insurance coverage or government subsidies
• While certain public health systems and private insurers have begun offering partial coverage, out-of-pocket expenses remain a deterrent for many prospective patients
• Overcoming these challenges through policy reforms, financial assistance programs, and technological innovations that reduce costs will be vital for expanding access and ensuring sustained growth of the ART market

Assisted Reproductive Technology ART Market Scope

The market is segmented on the basis of procedure, technology, product type, and end use.

• By Procedure

On the basis of procedure, the assisted reproductive technology (ART) market is segmented into fresh donor, fresh nondonor, frozen donor, frozen nondonor, and embryo/egg banking. The frozen nondonor segment held the largest market revenue share of 37.8% in 2025, driven by increasing success rates, lower costs, and scheduling flexibility.

The embryo/egg banking segment is expected to witness the fastest CAGR of 6.7% from 2025 to 2032, supported by rising demand for fertility preservation, particularly among women delaying childbearing.

• By Technology

On the basis of technology, the assisted reproductive technology market is segmented into in-vitro fertilization (IVF), artificial insemination - intrauterine insemination (AI-IUI), frozen embryo replacement (FER), surrogacy, ovulation induction, and others. The in-vitro fertilization (IVF) segment dominated the largest market revenue share of 56.7% in 2024, due to its high success rate, widespread clinical adoption, and technological advancements.

The frozen embryo replacement (FER) segment is projected to grow at the fastest CAGR of 7.3% during the forecast period, driven by improved outcomes and reduced health risks.

• By Product Type

On the basis of product type, the assisted reproductive technology market is segmented into women younger than age 35 and women older than age 35. The women younger than age 35 segment accounted for the largest market share of 58.4% in 2024, owing to higher treatment success rates and proactive fertility management.

The women older than age 35 segment is expected to grow at a CAGR of 6.9% from 2025 to 2032, fueled by delayed family planning and growing demand for donor egg programs and advanced ART techniques.

• By End Use

On the basis of end use, the assisted reproductive technology market is segmented into hospitals, fertility clinics, and others. The fertility clinics segment held the largest market revenue share of 71.6% in 2024, supported by their specialized services, expertise, and patient-centric care models.

The hospitals segment is expected to grow at the fastest CAGR of 6.4% from 2025 to 2032, due to expanding ART capabilities in multispecialty and government hospitals and increasing ART accessibility in developing nations.

Assisted Reproductive Technology ART Market Regional Analysis

• North America dominated the assisted reproductive technology (ART) market with the largest revenue share of 34.9% in 2024, driven by high infertility rates, delayed family planning, advanced healthcare infrastructure, and widespread access to ART procedures
• Consumers in the region benefit from a strong network of fertility clinics, favorable insurance coverage in select states, and the availability of cutting-edge technologies such as genetic testing, embryo freezing, and AI-assisted embryo selection
• This widespread adoption is further supported by high disposable incomes, growing awareness of reproductive health, and proactive government and private sector initiatives promoting fertility care, making ART a well-established solution for couples facing fertility challenges across the U.S. and Canada

U.S. Assisted Reproductive Technology (ART) Market Insight

The U.S. assisted reproductive technology (ART) market captured the largest revenue share of 78.4% within North America in 2024, driven by high infertility rates, growing acceptance of ART, and robust healthcare infrastructure. The country has one of the highest numbers of fertility clinics globally and leads in ART cycles performed annually. Innovations such as AI-assisted embryo selection and comprehensive genetic screening further contribute to the rapid market expansion. Government support, along with favorable reimbursement scenarios in certain states, also plays a critical role in driving growth.

Europe Assisted Reproductive Technology (ART) Market Insight

The Europe assisted reproductive technology market is projected to grow at a significant CAGR of 6.2% from 2025 to 2032, supported by rising awareness of fertility preservation and improved regulatory frameworks. The implementation of standardized treatment protocols and public funding for ART procedures in several European countries contribute to increased accessibility. Europe also benefits from strong demand across both domestic and cross-border reproductive care, making it a global hub for ART services.

U.K. Assisted Reproductive Technology (ART) Market Insight

The U.K. assisted reproductive technology market is expected to grow at a CAGR of 6.7% during the forecast period, driven by increasing fertility concerns, lifestyle-related infertility, and growing demand for advanced ART solutions. The National Health Service (NHS) provides partial coverage for ART treatments, and many private fertility centers offer cutting-edge services including egg freezing and donor programs. Regulatory clarity from the Human Fertilisation and Embryology Authority (HFEA) supports responsible market expansion.

Germany Assisted Reproductive Technology (ART) Market Insight

The Germany assisted reproductive technology market is projected to expand at a CAGR of 6.4% from 2025 to 2032, fueled by a strong focus on medical innovation, rising infertility rates, and increased public-private investment in reproductive health. Germany has well-established fertility clinics that offer comprehensive ART treatments, and recent policy shifts toward broader insurance coverage are expected to drive higher procedure volumes. Consumer preference for safety, ethical compliance, and evidence-based care positions Germany as a key player in Europe’s ART landscape.

Asia-Pacific Assisted Reproductive Technology (ART) Market Insight

The Asia-Pacific assisted reproductive technology market is poised to grow at the fastest CAGR of 7.4% during the forecast period (2025–2032), led by increasing infertility rates, lifestyle changes, and urbanization in countries such as China, India, and Japan. Governments across the region are promoting awareness and accessibility of reproductive healthcare. In addition, the growing affordability of ART treatments and the emergence of Asia as a hub for fertility tourism are driving exponential market growth.

China Assisted Reproductive Technology (ART) Market Insight

The China assisted reproductive technology market held the largest market revenue share in Asia-Pacific at 36.9% in 2024, fueled by increasing infertility rates, rising disposable income, and greater awareness of reproductive health. The country is witnessing rapid expansion of fertility clinics and increasing adoption of advanced ART methods such as IVF and genetic testing. Favorable government initiatives for population growth and strong domestic manufacturing of fertility-related equipment further strengthen China's leadership in the regional ART landscape.

India Assisted Reproductive Technology (ART) Market Insight

The India assisted reproductive technology market is projected to grow at a robust CAGR of 25.6% from 2025 to 2032, making it one of the fastest-growing markets in the region. In 2024, India accounted for 18.7% of the Asia-Pacific ART market revenue. Factors contributing to this growth include rising infertility rates, a younger population seeking fertility preservation, and growing awareness of ART procedures. In addition, India’s affordability, skilled specialists, and growing fertility tourism are boosting demand both domestically and internationally. Government policies such as the Assisted Reproductive Technology (Regulation) Act, 2021, are expected to further streamline market growth and enhance patient safety.

Assisted Reproductive Technology ART Market Share

The assisted reproductive technology ART industry is primarily led by well-established companies, including:

• California Cryobank (U.S.)
• Bloom Fertility Centre (India)
• CooperSurgical, Inc. (U.S.)
• Merck KGaA (Germany)
• Ferring B.V. (Switzerland)
• FUJIFILM Irvine Scientific (U.S.)
• Genea Pty Limited (Australia)
• Nidacon International AB (Sweden)
• Celmatix Inc. (U.S.)
• Esco Micro Pte Ltd. (Singapore)
• INVO Fertility (U.S.)
• Laboratoire CCD (France)
• Nikon Instruments Inc. (U.S.)
• ICU Medical, Inc. (U.S.)

Latest Developments in Global Assisted Reproductive Technology ART Market

• In March 2025, Astorg, a prominent pan-European private equity firm, announced the launch of Nexpring Health—a global MedTech company focused on Assisted Reproductive Technology (ART). Nexpring Health was formed through Astorg’s strategic acquisitions of Hamilton Thorne, Cook Medical’s Reproductive Health business, and the anticipated acquisition of FUJIFILM Irvine Scientific’s Medical Media Business
• In October 2024, SpOvum unveiled its cutting‑edge, AI‑driven platform—SpOvum ARTPT—designed to transform patient engagement in Assisted Reproductive Technology. By harnessing natural language processing, ARTPT delivers instant, conversational support around the clock, ensuring patients receive guidance even when clinics are closed

SKU-51909